Cognitively healthy centenarians appeared to be genetically protected against Alzheimer’s disease, genome-wide association studies showed. (Alzheimer’s and Dementia)
Steve Gleason, a former NFL player diagnosed with amyotrophic lateral sclerosis (ALS) more than a decade ago, published a memoir he typed with his eyes. (New York Times)
Cerebral microbleeds appeared to be associated with COVID-19 in the general population. (Brain Communications)
Researchers identified a genetic cause of spinocerebellar ataxia type 4. (Nature Genetics)
The proportion of life spent in Canada was tied to the incidence of multiple sclerosis (MS) in permanent immigrants. (Neurology)
The incidence of new-onset seizures was not significantly different between SARS-CoV-2 vaccine recipients and placebo recipients, a meta-analysis of clinical trial data showed. (JAMA Neurology)
Labcorp announced a new commercial blood test for glial fibrillary acidic protein (GFAP), which the company said could be used in MS, Alzheimer’s disease, glioblastoma, or traumatic brain injury.
Meanwhile, Quest Diagnostics added a commercial p-tau217 blood biomarker test for Alzheimer’s to its line-up.
The American Academy of Neurology issued a position statement on the term “excited delirium.”
NBA player Joel Embiid of the Philadelphia 76ers was diagnosed with Bell’s palsy. (AP)
More research confirmed that acid-suppression therapy — proton pump inhibitors and histamine H2 receptor antagonists — upped the odds of migraine and severe headache. (Neurology Clinical Practice)
Please enable JavaScript to view the